These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 10219506)

  • 21. The renaissance of centrally acting antihypertensive drugs.
    van Zwieten PA
    J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective imidazoline agonist moxonidine in obese hypertensive patients.
    Sanjuliani AF; de Abreu VG; Francischetti EA
    Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. I1 agents: a new approach to the treatment of hypertension.
    Dubar M; Pillion G
    Ann N Y Acad Sci; 1995 Jul; 763():642-58. PubMed ID: 7677384
    [No Abstract]   [Full Text] [Related]  

  • 24. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
    Mobini R; Fu M; Jansson PA; Bergh CH; Scharin Täng M; Waagstein F; Andersson B
    Clin Sci (Lond); 2006 Mar; 110(3):329-36. PubMed ID: 16209659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The contribution of I1-selective agents in the management of syndrome X.
    de Luca N; Argengiano L; Izzo R; Guerrera L; Iovino GL; Trimarco B
    Rev Port Cardiol; 2000 Apr; 19 Suppl 2():II33-5. PubMed ID: 10874855
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of moxonidine and clonidine on potassium excretion in Sprague-Dawley rats.
    Hohage H; Mehrens T; Matzkies F; Steinmetz M; Greven J
    Pharmacol Res; 1999 May; 39(5):357-61. PubMed ID: 10328993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effects of I(1)-antihypertensive agent moxonidine against neurogenic cardiac arrhythmias in halothane-anesthetized rabbits.
    Poisson D; Christen MO; Sannajust F
    J Pharmacol Exp Ther; 2000 Jun; 293(3):929-38. PubMed ID: 10869394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of imidazolines and imidazoline receptors role at the vascular level.
    Serban DN; Nechifor M; Slătineanu SM
    Rev Med Chir Soc Med Nat Iasi; 2000; 104(4):37-44. PubMed ID: 12089957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Catapresan (2-(2,6-dichlorphenylamino)-2-imidazoline-hydrochloride)--a new intraocular pressure lowering agent].
    Hasslinger C
    Klin Monbl Augenheilkd; 1969 Jan; 154(1):95-105. PubMed ID: 5364293
    [No Abstract]   [Full Text] [Related]  

  • 30. [Imidazoline receptors-normal and pathological factors].
    Nechifor M
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(3):438-43. PubMed ID: 12092170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors and drugs in the treatment of hypertension.
    Robertson JI
    J Hypertens Suppl; 1997 Jan; 15(1):S43-6. PubMed ID: 9050985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imidazoline Receptors in a Comprehensive Approach to Hypertension. Proceedings of an international symposium. Berlin, Germany, September 10, 1994.
    J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S1-67. PubMed ID: 8642799
    [No Abstract]   [Full Text] [Related]  

  • 33. Nutritional disorders: a target for sympathetic outflow-regulating drugs (imidazoline I1 receptor agonists).
    Rupp H
    Cardiovasc Drugs Ther; 1996 Jun; 10 Suppl 1():213-4. PubMed ID: 8827942
    [No Abstract]   [Full Text] [Related]  

  • 34. Imidazoline Receptor Workshop. Melbourne, Australia, 10 September 1997. Proceedings.
    J Auton Nerv Syst; 1998 Oct; 72(2-3):73-219. PubMed ID: 10084892
    [No Abstract]   [Full Text] [Related]  

  • 35. Selective imidazoline receptor agonists for metabolic syndrome.
    Krentz AJ; Evans AJ
    Lancet; 1998 Jan; 351(9097):152-3. PubMed ID: 9449863
    [No Abstract]   [Full Text] [Related]  

  • 36. [Imidazoline receptor agonists in the practical treatment of hypertension].
    Ol'binskaia LI; Bochenkov IuV; Alekseeva IL
    Ter Arkh; 1998; 70(2):86-8. PubMed ID: 9551585
    [No Abstract]   [Full Text] [Related]  

  • 37. [Agonists of the imidazoline receptors].
    Ol'binskaia LI; Bochenkov IuV
    Eksp Klin Farmakol; 1999; 62(2):68-72. PubMed ID: 10340136
    [No Abstract]   [Full Text] [Related]  

  • 38. [The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
    Dtsch Med Wochenschr; 1998 Aug; 123(33 Suppl):1-4. PubMed ID: 9739350
    [No Abstract]   [Full Text] [Related]  

  • 39. Selective imidazoline receptor agonists and lipid metabolism.
    Elisaf M; Tselepis A; Siamopoulos K
    Clin Chem Lab Med; 1999 Feb; 37(2):165. PubMed ID: 10219506
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.